PPARG and prostate cancer: It has been shown that LXRα and PPARγ heterodimerize with retinoid X receptor (RXR) and activating the two heterodimers (LXRα/RXR and PPARγ/RXR) could inhibit the prostate cancer cells proliferation 9.However, it is still not clear whether efatutazone has a similar effect on the gefitinib‐resistant lung adenocarcinoma cells (HCC827‐GR and PC9‐GR).